Charles Swingland joined PowderJect Pharmaceuticals Plc in 1996 as Senior Vice President of Corporate Services and General Counsel, after several years as a partner in a law firm in the City of London.
At PowderJect, Charles was responsible for all legal, intellectual property and compliance matters, and managed the legal aspects of several major acquisitions and fund-raisings, including the eventual sale of PowderJect to Chiron in 2003.
In 2004, he joined the senior management team of Zeneus Pharma, which was backed by Apax Partners and acquired the European speciality pharmaceuticals business of Elan Pharmaceuticals. During his time at Zeneus, he oversaw all of the company’s commercial transactions, including the acquisition of the original assets, the in-licensing of several new pharmaceutical products and the eventual sale to Cephalon Inc. in 2005.
In 2006, Charles co-founded Circassia Pharmaceuticals plc, which went public in March 2014 in the largest initial public offering of shares by a European biotechnology company. Charles was an executive director at the time of initial public offering and stood down to serve as a non-executive deputy chairman of Circassia until 2017.